legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

# Lyell Immunopharma, Inc Report Highlights and Financial Results

## Introduction
Lyell Immunopharma, Inc, a T-cell reprogramming company, reported its financial results for the first quarter ended March 31, 2024. The company is advancing a diverse pipeline of cell therapies for patients with solid tumors.

## Major Updates
– **LYL797 Clinical Data:** The company expects to share initial clinical data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product candidate, this quarter.
– **LYL845 Clinical Data:** The company is on track to report initial clinical data from the Phase 1 trial of LYL845 in the second half of 2024.
– **IND Submission:** An IND for the second-generation ROR1-targeted CAR T-cell product candidate is on track for submission this quarter.
– **Financial Status:** The company reported cash, cash equivalents, and marketable securities of $526.3 million as of March 31, 2024.

## CEO Statement
Lynn Seely, M.D., Lyell’s President and CEO, highlighted, “Our strong cash position is expected to fund operations through multiple milestones into 2027, including initial clinical data from our lead TIL program in the second half of this year…”

## AI legalese decoder Assistance
The AI legalese decoder can assist Lyell Immunopharma, Inc in translating complex legal documents and agreements into simple, easily understandable language. This can help improve communication with investors, partners, and regulatory authorities. By using AI technology, Lyell can streamline the interpretation of legal content, ensuring compliance and clarity in all aspects of their operations.

For further information, please visit [www.lyell.com](www.lyell.com).

**Contact:**
Ellen Rose
Senior Vice President, Communications and Investor Relations
[email protected]


legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link